HopeStage
Back to all studies
CompletedNCT03485287

MDMA-Assisted Psychotherapy for PTSD in Canada: An Open-Label Study

About this titleRead the official source — NCT03485287
Medication studyAges 18+Canada
The study in practice

Understand this study

Who was this study for?

Listed age limits: from 18 years.

Listed locations
Vancouver and 1 more locationSee all locations and recruitment
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: March 13, 2018
Recruitment status
Completed
Enrollment listed in the registry
4
Sponsor
Resilient Pharmaceuticals
Sponsor type
Unknown or unclear
Study type
Behavioral
Intervention type
Behavioural, Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
Canada
Age range
Over 18 Years
Official registry ID
NCT03485287
Official title
Show the full official title

An Open-Label, Multi-Site Phase 2 Study of the Safety and Effect of Manualized MDMA-Assisted Psychotherapy for the Treatment of Severe Posttraumatic Stress Disorder (Canada)

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Vancouver · Montreal

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Resilient Pharmaceuticals.

Did this study involve medication?

Yes. The study involved medication, including Midomafetamine HCl.

Who was this study for?

Listed age limits: from 18 years.

Want to explore more studies?

Explore studies